All In Biotech

Drug Trial Radar · NCT04735926

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency

Randomised, Double-blind, Double-dummy, Multicentre Trial to Evaluate the Efficacy and Safety of Three Different Weekly Dosages of Calcifediol Versus Placebo in Subjects With Either Vitamin D Deficiency or Insufficiency.

Last checked: Nov 19, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 674 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

674

Actual

Start

Dec 23, 2020

Primary completion

Jul 21, 2022

Study completion Apr 25, 2023

Sponsor

Lead sponsor
Faes Farma, S.A.Industry
Sponsor type
Industry
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, double-dummy, multicentre, dose-ranging clinical trial in subjects with vitamin D deficiency or insufficiency. Its general objective is to determine the efficacy and safety of different doses of calcifediol soft gelatin capsules (SGCs) compared to placebo.

Conditions

  • Vitamin D Deficiency
  • Vitamin D Insufficiency

Interventions

  • Calcifediol 75mcgDrug

    Soft gelatin capsule. Oral administration once per week

  • Calcifediol 100mcgDrug

    Soft gelatin capsule. Oral administration once per week

  • Calcifediol 125mcgDrug

    Soft gelatin capsule. Oral administration once per week.

  • PlaceboOther

    Soft gelatin capsule. Oral administration once per week.

  • PlaceboOther

    Soft gelatin capsule. Oral administration once per week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess efficacy for each cohort in terms of percentage of subjects achieving 25-OH-D levels ≥ 30 ng/mL and/or ≥ 20 ng/mL at 16 weeks of treatment.Time frame: 16 weeks

Locations

55 sites in 7 countries. Site status is shown where the registry gives one.

  • MC-1-Sevlievo Ltd.

    Sevlievo, Bulgaria

  • Diagnostic & Consultative Center "Sveta Anna" EOOD

    Sofia, Bulgaria

  • Individual Practice Ambulatory for Specialized Medical Care - Cardiology, Obstetrics and Gynecology

    Sofia, Bulgaria

  • IV MHAT - Sofia

    Sofia, Bulgaria

  • Lora - Medical center Sofia

    Sofia, Bulgaria

  • Medical Centre Asklepion - Research in human medicine

    Sofia, Bulgaria

  • Medical Centre Salvebis

    Sofia, Bulgaria

  • Alergologie Němcová, s.r.o.

    Brno, Czechia

  • Poliklinika Choceň - Neurologická ambulance

    Choceň, Czechia

  • MUDr. Eva Richterová - HK, s.r.o.

    Hradec Králové, Czechia

  • MUDr. Tomáš Edelsberger

    Krnov, Czechia

  • G-CENTRUM Olomouc s.r.o.

    Olomouc, Czechia

  • Centrum gynekologické rehabilitace s.r.o.

    Písek, Czechia

  • Centrum pro diagnostiku a léčbu myasthenia gravis - Neurologická klinika 1. LF UK a VFN v Praze

    Prague, Czechia

  • MediCel, s.r.o.

    Prague, Czechia

  • Milan Kvapil s.r.o.

    Prague, Czechia

  • RS centrum - Neurologická klinika 1.LF UK a VFN v Praze

    Prague, Czechia

  • Ordinace MediFem, s.r.o.

    Teplice, Czechia

  • CHU Bordeaux, Hôpital Pellegrin

    Bordeaux, France

  • CHR Orléans, Service Rhumatologie

    Orléans, France

  • CHU Saint Etienne, Hôpital Nord

    Saint-Etienne, France

  • CHU Purpan

    Toulouse, France

  • Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico -UOC Endocrinologia e Malattie Metaboliche

    Milan, Italy

  • IRCCS Ospedale San Raffaele /Unità di Endocrinologia

    Milan, Italy

  • Azienda Ospedaliero Universitaria - Università degli Studi della Campania Luigi Vanvitelli - UOC di Medicina Fisica e Riabilitazione

    Naples, Italy

  • UOC di Riabilitazione -Azienda Ospedaliero Universitaria Paolo Giaccone Palermo

    Palermo, Italy

  • AOU Pisana - Centro di Farmacologia Clinica per la Sperimentazione dei Farmaci

    Pisa, Italy

  • Fondazione PTV -Policlinico Ospedaliero Universitario Tor Vergata - U.O.C. Ortopedia e Traumatologia

    Roma, Italy

  • Institut za reumatologiju

    Belgrade, Serbia

  • Klinički centar Kragujevac, Centar za reumatologiju, alergologiju i kliničku imunologiju, Odeljenje za reumatologiju

    Kragujevac, Serbia

  • Institut za lečenje i rehabilitaciju "Niška Banja" Niš, Klinika za reumatologiju

    Niška Banja, Serbia

  • Klinički centar Vojvodine, Klinika za endokrinologiju, dijabetes i bolesti metabolizma

    Novi Sad, Serbia

  • Specijalna bolnica za reumatske bolesti Novi Sad

    Novi Sad, Serbia

  • Opšta bolnica "Đorđe Joanović" Zrenjanin, Odeljenje za reumatologiju

    Zrenjanin, Serbia

  • IN MEDIC s.r.o., Neurologická ambulancia

    Bardejov, Slovakia

  • ALERGO H2B, s.r.o., Ambulancia klinickej imunológie a alergológie

    Komárno, Slovakia

  • ALERSA, s.r.o., Ambulancia klinickej imunológie a alergológie

    Košice, Slovakia

  • Endomed, s.r.o. - Gastroenterologická ambulancia

    Košice, Slovakia

  • DANIMED, s.r.o., Ambulancia klinickej imunológie a alergológie

    Levice, Slovakia

  • KARDIO 1, s.r.o., Kardiologická ambulancia

    Lučenec, Slovakia

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.